Zoetis Beheer

Beheer criteriumcontroles 4/4

De CEO Zoetis is Kristin Peck, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.24M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde $ 13.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 11 jaar.

Belangrijke informatie

Kristin Peck

Algemeen directeur

US$15.2m

Totale compensatie

Percentage CEO-salaris	7.9%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	11yrs

Recente managementupdates

Recent updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Analyse CEO-vergoeding

Hoe is Kristin Peck's beloning veranderd ten opzichte van Zoetis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$15m	US$1m	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$14m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$13m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$10m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$3m	US$690k	US$2b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$1b
Dec 31 2018	US$3m	US$675k	US$1b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$978m
Dec 31 2017	US$3m	US$655k	US$864m

Compensatie versus markt: De totale vergoeding ($USD 15.24M ) Kristin } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Kristin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kristin Peck (53 yo)

4.8yrs

Tenure

US$15,237,853

Compensatie

Ms. Kristin C. Peck serves as an Independent Director at BlackRock, Inc. since joining on September 29, 2021. She has been the Chief Executive Officer of Zoetis Inc. since January 01, 2020 and its Director...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristin Peck	CEO & Director	4.8yrs	US$15.24m	0.018% $ 14.0m
Wetteny Joseph	Executive VP & CFO	3.4yrs	US$4.25m	0.0034% $ 2.7m
Wafaa Mamilli	EVP, Chief Digital & Tech. Officer	2yrs	US$2.69m	0.0015% $ 1.2m
Robert Polzer	Executive VP and President of Research & Development	9.8yrs	US$2.44m	0.00095% $ 746.8k
Steven Frank	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Roxanne Lagano	Executive VP	less than a year	geen gegevens	0.0035% $ 2.7m
William Price	VP & Chief Communications Officer	no data	geen gegevens	geen gegevens
Julie Fuller	Executive VP	less than a year	geen gegevens	0.000020% $ 15.7k
Jeannette Astorga	Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer	4.2yrs	geen gegevens	0.00015% $ 117.9k
Nick Ashton	Executive VP and President of Global Manufacturing & Supply	2.5yrs	geen gegevens	0.00014% $ 110.1k
Jamie Brannan	Executive VP and Group President International Operations of Aquaculture & Global Diagnostics	no data	geen gegevens	0.00043% $ 338.0k
Rimma Driscoll	Executive VP and Head of Global Strategy	2yrs	geen gegevens	0.0011% $ 833.3k

2.5yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ZTS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kristin Peck	CEO & Director	5.1yrs	US$15.24m	0.018% $ 14.0m
Louise Parent	Independent Director	11.3yrs	US$370.00k	0.0030% $ 2.4m
Michael McCallister	Independent Non-Executive Chairman	11.8yrs	US$490.00k	0.0057% $ 4.5m
Paul Bisaro	Independent Director	9.5yrs	US$340.00k	0.0048% $ 3.8m
Frank D'Amelio	Independent Director	12.3yrs	US$340.50k	0.0033% $ 2.6m
Sanjay Khosla	Independent Director	11.4yrs	US$340.00k	0.0022% $ 1.7m
Robert Scully	Independent Director	11.4yrs	US$365.00k	0.0044% $ 3.4m
Gavin D. Hattersley	Independent Director	less than a year	geen gegevens	0.00017% $ 133.6k
Gregory Norden	Independent Director	11.8yrs	US$365.00k	0.0034% $ 2.6m
Willie Reed	Independent Director	10.7yrs	US$370.00k	0.0022% $ 1.7m
Vanessa Broadhurst	Independent Director	2.3yrs	US$341.00k	0.00023% $ 180.8k
Antoinette Leatherberry	Independent Director	3.9yrs	US$340.00k	0.00049% $ 385.2k

11.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ZTS zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).

Zoetis Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Executive VP & CFO exercised options and sold US$2.4m worth of stock

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Employee Advisor notifies of intention to sell stock

Zoetis Inc. Announces Executive Changes

Zoetis Inc., Annual General Meeting, May 22, 2024

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Recent updates

Zoetis Inc. Raises Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Second quarter dividend of US$0.43 announced

Zoetis Inc. Declares Fourth Quarter 2024 Dividend, Payable on December 3, 2024

Zoetis: A Solid Choice For The Young Dividend Growth Investor

Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Zoetis: Investing In Pet Health And Portfolio Wealth

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

Zoetis to Introduce First Cartridge-Based AI-Powered Hematology Analyzer

There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Now 22% undervalued

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Zoetis Inc. Raises Earnings Guidance for the Year 2024

Zoetis Inc. (NYSE:ZTS) announces an Equity Buyback for $6,000 million worth of its shares.

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Upcoming dividend of US$0.43 per share

Executive VP & CFO exercised options and sold US$2.4m worth of stock

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

Employee Advisor notifies of intention to sell stock

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.